Menopause and Body Composition: Hormones, DHEA and Peptide Research
Menopause can change body composition even when the scale follows a familiar pattern. In the longitudinal SWAN study, fat gain accelerated and lean mass began to decline during the menopausal transition, without a corresponding acceleration in overall weight gain. That distinction matters when interpreting hormone therapy, metabolic supplements and peptide research. [1]
The studies below address different questions: preservation of lean tissue, fat distribution, insulin sensitivity and hormone release. Their doses describe research exposures, not a combined menopause treatment schedule.
Hormone therapy: body composition can change without weight loss
The Women’s Health Initiative substudy
Among 835 postmenopausal women followed for three years, estrogen plus progestin reduced lean soft-tissue loss and produced a small improvement in trunk-to-leg fat distribution compared with placebo. Participants averaged 63.1 years of age and were, on average, 13.8 years past menopause. [2]
Three-year change | Estrogen plus progestin | Placebo |
Lean soft-tissue mass | −0.04 kg | −0.44 kg |
Trunk-to-leg fat-mass ratio | −0.025 | +0.004 |
The parent trial used an oral daily tablet containing conjugated equine estrogens 0.625 mg and medroxyprogesterone acetate 2.5 mg. These are not the same preparations as transdermal estradiol and micronized progesterone. The body-composition effects were small; the parent trial also found important cardiovascular and breast-cancer risks with its tested regimen. A favourable composition endpoint alone does not establish an overall health benefit. [2,3]
Oral versus transdermal estrogen
A 12-month study compared 13 hysterectomized postmenopausal women taking oral conjugated estrogen 0.625 mg daily with 10 using transdermal estradiol delivering 50 micrograms daily. Lean mass and lipid oxidation increased in the transdermal group and decreased in the oral group. Total fat mass increased with oral treatment but did not change with transdermal treatment. Neither group had a significant change in body weight, visceral-fat area or energy expenditure. [4]
This small study suggests that formulation and route can influence metabolic measurements. It does not show that an estrogen patch reliably produces weight loss, and its estrogen-only design does not test a combined estradiol–progesterone regimen.
DHEA: promising short-term findings, inconsistent longer-term results
In a six-month randomized trial, 56 adults aged 65–78 years—28 women and 28 men—received DHEA 50 mg/day or placebo. Visceral-fat area changed by −13 cm² with DHEA versus +3 cm² with placebo; subcutaneous abdominal-fat area changed by −13 versus +2 cm². An insulin-sensitivity index also improved. These were mixed-sex older-adult results, not findings specifically in women gaining weight while using menopausal hormone therapy. [5]
The larger DAWN trial tested oral DHEA 50 mg daily for one year in 225 adults aged 55–85. Body composition did not improve in either sex. A separate two-year trial likewise found no significant DHEA benefit for body composition or insulin sensitivity. The early findings therefore do not establish DHEA as a dependable menopause weight-loss intervention. [6,7]
Growth-hormone release is not a body-composition outcome
The human ipamorelin study cited in this research framework measured drug exposure and growth-hormone release in healthy men. Eight participants were studied at each of five intravenous dose levels: 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg, delivered over 15 minutes. A single growth-hormone pulse peaked at about 0.67 hours. It was not a trial of nightly 100-microgram dosing, menopausal fat loss or long-term muscle preservation. [8]
A separate combination experiment used GHRH(1–29)NH₂ and hexarelin, each at 100 micrograms as an intravenous bolus. Hexarelin is not ipamorelin. Results from that experiment cannot validate a CJC-no-DAC/ipamorelin schedule. [9]
MOTS-c and SS-31: two distinct mitochondrial research approaches
MOTS-c and metabolic signalling
Lee and colleagues studied MOTS-c in cells and mice. In one experiment, eight-week-old male CD-1 mice eating a diet providing 60% of calories from fat received 0.5 mg/kg daily by intraperitoneal injection for eight weeks. Treatment prevented diet-induced obesity and insulin resistance, with AMPK-related signalling among the mechanisms investigated. This was prevention in male mice, not a menopause treatment trial. [10]
Our MOTS-c research overview explains the broader signalling work. The mouse exposure above does not establish a human dose or support replacing daily administration with a twice-weekly schedule.
SS-31 and mitochondrial oxidative stress
Anderson and colleagues administered SS-31 at 1.5 mg/kg daily by intraperitoneal injection in high-fat-fed male rats during six-week treatment studies. SS-31 reduced excess mitochondrial hydrogen-peroxide emission and preserved insulin sensitivity. Although the paper also included human muscle investigations, the SS-31 treatment findings came from rodents. They do not establish efficacy for menopausal weight gain. [11]
Metabolic supplements require the same dose and endpoint checks
A randomized, placebo-controlled trial in 24 adults with metabolic syndrome tested berberine hydrochloride 500 mg three times daily before meals for three months. It reported improvements in insulin sensitivity and selected metabolic measures. This small study did not specifically investigate menopause or test berberine alongside the hormone and peptide combination discussed here. [12]
The cited boron experiment involved 12 postmenopausal women in a metabolic unit. It used 3 mg/day after 119 days on a low-boron diet and measured mineral handling and sex-steroid concentrations. It did not establish weight-loss efficacy or validate 10 mg/day as a menopause protocol. [13]
What would demonstrate a useful menopause intervention?
A useful trial must distinguish fat loss from lean-tissue loss, measure insulin sensitivity separately from hormone concentrations, and report adverse effects alongside benefits. A growth-hormone pulse, an altered mineral measurement and preserved insulin sensitivity in a rat are different outcomes; combining them does not demonstrate that a multi-compound regimen works.
The hormone studies provide direct human body-composition evidence, with modest effects and important differences between preparations. DHEA results are inconsistent. The cited mitochondrial peptide experiments support further research, but do not supply a tested menopause treatment schedule. For a practical guide to those distinctions, see how to read a peptide research paper.